Consolidated Statements of Operations - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023
Revenues		$ 1,228,409	$ 1,046,193
Cost of goods sold		984,038	837,883
Gross profit		244,371	208,310
Selling, general, and administrative expenses		307,291	167,364
Operating income (loss)		(62,920)	40,946
Other expenses:
Interest expense		3,278	2,859
Other expense, net		279	367
Total other expenses		3,557	3,226
Income (loss) before income taxes		(66,477)	37,720
Provision for income taxes		4,556	0
Net income (loss)		(71,033)	37,720
Less net income attributable to Guardian Pharmacy, LLC prior to the Corporate Reorganization		22,760	23,902
Less net income attributable to non-controlling interests		16,254	$ 13,818
Net income (loss) attributable to Guardian Pharmacy Services, Inc.		$ (110,047)
Class A and Class B common stock [Member]
Net income (loss) per share of Class A and Class B common stock
Basic	[1]	$ (1.77)
Diluted	[1]	$ (1.77)
Weighted-average Class A and Class B common shares outstanding
Basic		62,005,811
Diluted		62,005,811

[1] Basic and diluted net income (loss) per share of Class A and Class B common stock is applicable only for the period from September 27, 2024 through December 31, 2024, which is the period following the initial public offering (“IPO”) and related Corporate Reorganization (as defined in Note 1 to the Consolidated Financial Statements). See Note 10 Basic and Diluted Loss Per Share for the number of shares used in the computation of net income (loss) per share of Class A and Class B common stock and the basis for the computation of net income (loss) per share.